Human cytomegalovirus and kidney transplantation: A clinician's update

American Journal of Kidney Diseases

Volumn 58, Issue 1, 2011, Pages 118-126

  De Keyzer, Kristel ^a,b   Van Laecke, Steven ^a   Peeters, Patrick ^a   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b AZ Monica   (Belgium)

Author keywords

Cytomegalovirus; diagnosis; kidney transplantation; prevention; risk; treatment

Indexed keywords

ACICLOVIR; ANTIGEN; CYCLOSPORIN; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; LYMPHOCYTE ANTIBODY; VALACICLOVIR; VALGANCICLOVIR; VIRUS ENZYME;

AGE; BONE MARROW SUPPRESSION; CYTOMEGALOVIRUS INFECTION; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT SURVIVAL; HUMAN; HUMAN CYTOMEGALOVIRUS; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN DONOR; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SEROLOGY; VIRUS DETECTION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; IMMUNOCOMPROMISED HOST; KIDNEY TRANSPLANTATION; RISK FACTORS;

EID: 79959355125     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2011.04.010     Document Type: Review

References (62)

1. T. Crough, and R. Khanna Immunobiology of human cytomegalovirus: from bench to bedside Clin Microbiol Rev 22 1 2009 76 98
2. D.C. Brennan Cytomegalovirus in renal transplantation J Am Soc Nephrol 12 4 2001 848 855 (Pubitemid 32246715)
3. A. Humar, D. Snydman AST Infectious Diseases Community of Practice Cytomegalovirus in solid organ transplant recipients Am J Transplant 9 suppl 4 2009 S78 S86
4. P. Reinke, S. Prsch, F. Kern, and H.D. Volk Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients Transpl Infect Dis 1 3 1999 157 164
5. S.J. Kim, T.K. Varghese, and Z. Zhang Renal ischemia/reperfusion injury activates the enhancer domain of the human cytomegalovirus major immediate early promoter Am J Transplant 5 7 2005 1606 1613 (Pubitemid 40916229)
6. Z. Zhang, S.J. Kim, T. Varghese, G. Thomas, M. Hummel, and M. Abecassis TNF receptor independent activation of the cytomegalovirus major immediate early enhancer in response to transplantation Transplantation 85 7 2008 1039 1045 (Pubitemid 351543169)
7. S. Prsch, C.E. Wendt, and P. Reinke A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation Virology 272 2 2000 357 365 (Pubitemid 30480195)
8. A.S. Kutza, E. Muhl, H. Hackstein, H. Kirchner, and G. Bein High incidence of active cytomegalovirus infection among septic patients Clin Infect Dis 26 5 1998 1076 1082 (Pubitemid 128751524)
9. M.M. Addo, and E.S. Rosenberg Cellular immune responses in transplantation-associated chronic viral infections Transpl Infect Dis 4 1 2002 31 40 (Pubitemid 34786822)
10. C. Legendre, and M. Pascual Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences Clin Infect Dis 46 5 2008 732 740 (Pubitemid 351321558)
11. C.N. Kotton, D. Kumar, and A.M. Caliendo International consensus guidelines on the management of cytomegalovirus in solid organ transplantation Transplantation 89 7 2010 779 794
12. P. Ljungman, P. Griffiths, and C. Paya Definitions of cytomegalovirus infection and disease in transplant recipients Clin Infect Dis 34 8 2002 1094 1097 (Pubitemid 34289682)
13. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO clinical practice guideline for the care of kidney transplant recipients Chapter 13: viral diseases Am J Transplant 9 suppl 3 2009 S44 S58
14. L. Marsano, R.P. Perrillo, and M.W. Flye Comparison of culture and serology for the diagnosis of cytomegalovirus infection in kidney and liver transplant recipients J Infect Dis 161 3 1990 454 461 (Pubitemid 20107945)
15. R.R. Razonable, C.V. Paya, and T.F. Smith Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients J Clin Microbiol 40 3 2002 746 752 (Pubitemid 34208617)
16. H. Piiparinen, I. Helanter, and M. Lappalainen Quantitative PCR in the diagnosis of CMV infection and in the monitoring of viral load during the antiviral treatment in renal transplant patients J Med Virol 76 3 2005 367 372 (Pubitemid 40770893)
17. H. Li, J.S. Dummer, W.R. Estes, S. Meng, P.F. Wright, and Y.W. Tang Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients J Clin Microbiol 41 1 2003 187 191 (Pubitemid 36098574)
18. T. Reischig, P. Jindra, M. Svecová, S. Kormunda, K. Opatrn Jr, and V. Treska The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection J Clin Virol 36 2 2006 146 151
19. I. Garrigue, S. Boucher, and L. Couzi Whole blood real-time quantitative PCR for cytomegalovirus infection follow-up in transplant recipients J Clin Virol 36 1 2006 72 75 (Pubitemid 44360573)
20. X.L. Pang, J.D. Fox, J.M. Fenton, G.G. Miller, A.M. Caliendo, J.K. Preiksaitis American Society of Transplantation Infectious Diseases Community of Practice; Canadian Society of Transplantation Interlaboratory comparison of cytomegalovirus viral load assays Am J Transplant 9 2 2009 258 268
21. J.A. Khoury, G.A. Storch, and D.L. Bohl Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients Am J Transplant 6 9 2006 2134 2143 (Pubitemid 44199547)
22. P.L. Hibberd, N.E. Tolkoff-Rubin, and A.B. Cosimi Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3 Transplantation 53 1 1992 68 72
23. S. Sagedal, K.P. Nordal, and A. Hartmann The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients Am J Transplant 2 9 2002 850 856 (Pubitemid 36306840)
24. S. Sagedal, A. Hartmann, and K.P. Nordal Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival Kidney Int 66 1 2004 329 337 (Pubitemid 38870110)
25. D.C. Brennan, K.A. Garlock, and G.G. Singer Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients Transplantation 64 12 1997 1843 1846 (Pubitemid 28041727)
26. D. Lowance, H.H. Neumayer, and C.M. Legendre Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group N Engl J Med 340 19 1999 1462 1470 (Pubitemid 29220545)
27. T. Reischig, K. Opatrny Jr, M. Bouda, V. Treska, P. Jindra, and M. Svecova A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation Transpl Int 15 12 2002 615 622 (Pubitemid 36068176)
28. T. Reischig, P. Jindra, and J. Mares Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection Transplantation 79 3 2005 317 324 (Pubitemid 40299538)
29. T. Reischig, P. Jindra, O. Hes, M. Svecová, J. Klaboch, and V. Treska Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation Am J Transplant 8 1 2008 69 77
30. T. Reischig, P. Jindra, O. Hes, M. Bouda, S. Kormunda, and V. Treska Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis Transplantation 87 3 2009 436 444
31. A. Humar, K.J. Gillingham, W.D. Payne, D.L. Dunn, D.E. Sutherland, and A.J. Matas Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients Transplantation 68 12 1999 1879 1883 (Pubitemid 30027341)
32. A. Humar, Y. Lebranchu, and F. Vincenti The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients Am J Transplant 10 5 2010 1228 1237
33. V. Kliem, L. Fricke, T. Wollbrink, M. Burg, J. Radermacher, and F. Rohde Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial Am J Transplant 8 5 2008 975 983 (Pubitemid 351537752)
34. I.D. Pavlopoulou, V.P. Syriopoulou, and H. Chelioti A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients Clin Microbiol Infect 11 9 2005 736 743 (Pubitemid 41167340)
35. R. San Juan, J.M. Aguado, C. Lumbreras RESITRA Network of the Spanish Study Group of Infection in Transplantation Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation Clin Infect Dis 47 7 2008 875 882
36. S. Bataille, V. Moal, and J. Gaudart Cytomegalovirus risk factors in renal transplantation with modern immunosuppression Transpl Infect Dis 12 6 2010 480 488
37. I. Helanter, L. Kyllnen, I. Lautenschlager, K. Salmela, and P. Koskinen Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis Am J Transplant 10 9 2010 2026 2032
38. A.M. Doyle, K.M. Warburton, S. Goral, E. Blumberg, R.A. Grossman, and R.D. Bloom 24-Week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course Transplantation 81 8 2006 1106 1111
39. M.O. Kaisar, R.M. Kirwan, and G.M. Strutton Cutaneous manifestations of cytomegalovirus disease in renal transplant recipients: a case series Transpl Infect Dis 10 3 2008 209 213 (Pubitemid 351704005)
40. A. Humar, K. Gillingham, W.D. Payne, D.E. Sutherland, and A.J. Matas Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease Transplantation 70 2 2000 310 313 (Pubitemid 30602749)
41. R.S. Kalil, S.L. Hudson, and R.S. Gaston Determinants of cardiovascular mortality after renal transplantation: a role for cytomegalovirus? Am J Transplant 3 1 2003 79 81 (Pubitemid 36306828)
42. K. Solez, R.B. Colvin, and L.C. Racusen Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN') Am J Transplant 7 3 2007 418 526
43. R.R. Razonable, R.A. Brown, A. Humar, E. Covington, E. Alecock, C.V. Paya PV16000 Study Group Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease J Infect Dis 192 8 2005 1331 1339 (Pubitemid 41401145)
44. R. Maez, M.C. Breinig, and P. Linden Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease J Infect Dis 176 6 1997 1462 1467 (Pubitemid 27518144)
45. E. Razeghi, A. Hadadi, P. Khashayar, and G. Pourmand Kaposi's sarcoma in renal transplantation: report of three cases Clin Nephrol 71 2 2009 214 216
46. S. Pouria, O.I. State, W. Wong, and B.M. Hendry CMV infection is associated with transplant renal artery stenosis QJM 91 3 1998 185 189 (Pubitemid 28115851)
47. J. Hjelmesæth, S. Sagedal, and A. Hartmann Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation Diabetologia 47 9 2004 1550 1556 (Pubitemid 39371637)
48. K. De Keyzer, S. Van Laecke, P. Peeters, and R. Vanholder De novo thrombotic microangiopathy induced by cytomegalovirus infection leading to renal allograft loss Am J Nephrol 32 5 2010 491 496
49. R.A. El-Sabrout, B. Radovancevic, V. Ankoma-Sey, and C.T. Van Buren Guillain-Barré syndrome after solid organ transplantation Transplantation 71 9 2001 1311 1316 (Pubitemid 32507154)
50. S.R. Keithi-Reddy, R.M. Chakravarthi, S.M. Hussaini, R.R. Venkatapuram, and J.M. Murthy Cytomegalovirus disease with Guillain-Barré syndrome in a cadaver renal allograft recipient: cause or coincidence Int Urol Nephrol 39 3 2007 967 970 (Pubitemid 47365417)
51. C.G. ter Meulen, J.F. Wetzels, and L.B. Hilbrands The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation Nephrol Dial Transplant 15 5 2000 711 714 (Pubitemid 30242993)
52. A.C. Webster, L.P. Ruster, and R. McGee Interleukin 2 receptor antagonists for kidney transplant recipients Cochrane Database Syst Rev 2010 10.1002/14651858.CD003897.pub3
53. R.H. Rubin, S.A. Kemmerly, and D. Conti Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis Transpl Infect Dis 2 3 2000 112 117
54. E.M. Hodson, J.C. Craig, G.F.M. Strippoli, and A.C. Webster Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients Cochrane Database Syst Rev 2008 10.1002/14651858.CD003774.pub3 (Pubitemid 351807481)
55. J. Soul-Lawton, E. Seaber, N. On, R. Wootton, P. Rolan, and J. Posner Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans Antimicrob Agents Chemother 39 12 1995 2759 2764
56. K.D. Lake New prophylactic treatment strategy for cytomegalovirus disease Am J Health Syst Pharm 60 23 2003 S13 S16 (suppl 8)
57. C. Paya, A. Humar, E. Dominguez Valganciclovir Solid Organ Transplant Study Group Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients Am J Transplant 4 4 2004 611 620 (Pubitemid 38523584)
58. A.C. Kalil, J. Levitsky, E. Lyden, J. Stoner, and A.G. Freibeld Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients Ann Intern Med 143 12 2005 870 880 (Pubitemid 46202222)
59. G.F. Strippoli, E.M. Hodson, C. Jones, and J.C. Craig Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients Transplantation 81 2 2006 139 145
60. A. sberg, A. Humar, and H. Rollag Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients Am J Transplant 7 9 2007 2106 2113 (Pubitemid 47247057)
61. A.P. Limaye, L. Corey, D.M. Koelle, C.L. Davis, and M. Boeckh Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants Lancet 356 9230 2000 645 649 (Pubitemid 30627592)
62. A.P. Limaye Ganciclovir-resistant cytomegalovirus in organ transplant recipients Clin Infect Dis 35 7 2002 866 872